Claudia Hawkins1, Jennifer Grant2, Lauren Rose Ammerman3, Frank Palella2, Milena Mclaughlin4, Richard Green5, Donna Mcgregor2, Valentina Stosor2. 1. Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA c-hawkins@md.northwestern.edu. 2. Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3. Feinberg School of Medicine, Chicago, IL, USA. 4. Midwestern University Chicago College of Pharmacy, Downers Grove, IL, USA Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA. 5. Department of Medicine, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
OBJECTIVES: There are few data on the real-world experience of FDA-approved oral hepatitis C virus (HCV) direct-acting antiviral (DAA) drug combinations in HIV/HCV-coinfected patients. We evaluated the safety and efficacy of DAA therapies in a cohort of HIV/HCV patients in a large urban clinic in Chicago. METHODS: HIV/HCV-coinfected adults (≥18 years) enrolled in the Northwestern University Viral Hepatitis Registry between January 2013 and June 2015 were analysed. Treated patients received one of the following DAA combinations: sofosbuvir/ledipasvir, sofosbuvir/ribavirin, sofosbuvir/simeprevir or paritaprevir/ritonavir/ombitasvir/dasabuvir ± ribavirin. The primary outcome was sustained virological response at 12 weeks after DAA completion (SVR12). RESULTS: Seventy-seven HIV/HCV patients were evaluated for DAA therapy. Most patients were male (62/77, 81%) and infected with HCV genotype 1 (67/77, 87%). Some 32/77 (42%) were cirrhotic and 29/77 (38%) had received prior treatment with an IFN-containing regimen. DAA therapy was more likely to be started in Caucasians than persons of other ethnicities (P = 0.01). The overall SVR12 rate was 92% in 52 patients who completed therapy and had follow-up by the end of the study: sofosbuvir/simeprevir, 32/33 (97%); sofosbuvir/ribavirin, 4/7 (57%); sofosbuvir/ledipasvir, 11/11 (100%); and paritaprevir/ritonavir/ombitasvir/dasabuvir, 1/1 (100%). Four patients relapsed after therapy with sofosbuvir/simeprevir (n = 1) or sofosbuvir/ribavirin (n = 3). Adverse events were uncommon and did not result in DAA treatment interruption or discontinuation. CONCLUSIONS: The HCV DAA combinations of sofosbuvir/ledipasvir and sofosbuvir/simeprevir were highly effective and well tolerated in this diverse population of HIV/HCV-coinfected patients, many of whom had advanced liver disease. HIV coinfection should not be considered a barrier to successful HCV treatment with DAAs.
OBJECTIVES: There are few data on the real-world experience of FDA-approved oral hepatitis C virus (HCV) direct-acting antiviral (DAA) drug combinations in HIV/HCV-coinfectedpatients. We evaluated the safety and efficacy of DAA therapies in a cohort of HIV/HCVpatients in a large urban clinic in Chicago. METHODS:HIV/HCV-coinfected adults (≥18 years) enrolled in the Northwestern University Viral Hepatitis Registry between January 2013 and June 2015 were analysed. Treated patients received one of the following DAA combinations: sofosbuvir/ledipasvir, sofosbuvir/ribavirin, sofosbuvir/simeprevir or paritaprevir/ritonavir/ombitasvir/dasabuvir ± ribavirin. The primary outcome was sustained virological response at 12 weeks after DAA completion (SVR12). RESULTS: Seventy-seven HIV/HCVpatients were evaluated for DAA therapy. Most patients were male (62/77, 81%) and infected with HCV genotype 1 (67/77, 87%). Some 32/77 (42%) were cirrhotic and 29/77 (38%) had received prior treatment with an IFN-containing regimen. DAA therapy was more likely to be started in Caucasians than persons of other ethnicities (P = 0.01). The overall SVR12 rate was 92% in 52 patients who completed therapy and had follow-up by the end of the study: sofosbuvir/simeprevir, 32/33 (97%); sofosbuvir/ribavirin, 4/7 (57%); sofosbuvir/ledipasvir, 11/11 (100%); and paritaprevir/ritonavir/ombitasvir/dasabuvir, 1/1 (100%). Four patients relapsed after therapy with sofosbuvir/simeprevir (n = 1) or sofosbuvir/ribavirin (n = 3). Adverse events were uncommon and did not result in DAA treatment interruption or discontinuation. CONCLUSIONS: The HCVDAA combinations of sofosbuvir/ledipasvir and sofosbuvir/simeprevir were highly effective and well tolerated in this diverse population of HIV/HCV-coinfectedpatients, many of whom had advanced liver disease. HIV coinfection should not be considered a barrier to successful HCV treatment with DAAs.
Authors: Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Anu Osinusi; Kerry Townsend; Anita Kohli; Amy Nelson; Cassie Seamon; Eric G Meissner; Dimitra Bon; Rachel Silk; Chloe Gross; Angie Price; Mohammad Sajadi; Sreetha Sidharthan; Zayani Sims; Eva Herrmann; John Hogan; Gebeyehu Teferi; Rohit Talwani; Michael Proschan; Veronica Jenkins; David E Kleiner; Brad J Wood; G Mani Subramanian; Phillip S Pang; John G McHutchison; Michael A Polis; Anthony S Fauci; Henry Masur; Shyam Kottilil Journal: JAMA Date: 2015 Mar 24-31 Impact factor: 56.272
Authors: Mark S Sulkowski; Joseph J Eron; David Wyles; Roger Trinh; Jay Lalezari; Chia Wang; Jihad Slim; Laveeza Bhatti; Joseph Gathe; Peter J Ruane; Richard Elion; Fritz Bredeek; Robert Brennan; Gary Blick; Amit Khatri; Krystal Gibbons; Yiran B Hu; Linda Fredrick; Gretja Schnell; Tami Pilot-Matias; Rakesh Tripathi; Barbara Da Silva-Tillmann; Barbara McGovern; Andrew L Campbell; Thomas Podsadecki Journal: JAMA Date: 2015 Mar 24-31 Impact factor: 56.272
Authors: Adeel A Butt; Amy C Justice; Melissa Skanderson; Michael O Rigsby; Chester B Good; C Kent Kwoh Journal: Gut Date: 2006-09-27 Impact factor: 23.059
Authors: Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski Journal: N Engl J Med Date: 2015-07-21 Impact factor: 91.245
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Sebastian Steiner; Theresa Bucsics; Philipp Schwabl; Mattias Mandorfer; Bernhard Scheiner; Maximilian Christopher Aichelburg; Katharina Grabmeier-Pfistershammer; Peter Ferenci; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger Journal: Wien Klin Wochenschr Date: 2017-01-27 Impact factor: 1.704
Authors: Manish Patel; Saira Rab; Aley G Kalapila; Alison Kyle; Ike Solomon Okosun; Lesley Miller Journal: Open Forum Infect Dis Date: 2017-04-05 Impact factor: 3.835
Authors: Lauren P Jatt; Malini M Gandhi; Rong Guo; Adam Sukhija-Cohen; Debika Bhattacharya; Chi-Hong Tseng; Kara W Chew Journal: J Gastroenterol Hepatol Date: 2020-09-08 Impact factor: 4.029